Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lifecore Biomedical, Inc. \De\ (LFCR) Current Deferred Revenue (2016 - 2024)

Historic Current Deferred Revenue for Lifecore Biomedical, Inc. \De\ (LFCR) over the last 16 years, with Q4 2024 value amounting to $9.0 million.

  • Lifecore Biomedical, Inc. \De\'s Current Deferred Revenue rose 473.26% to $9.0 million in Q4 2024 from the same period last year, while for Nov 2024 it was $9.0 million, marking a year-over-year increase of 473.26%. This contributed to the annual value of $10.6 million for FY2024, which is 5117.14% up from last year.
  • Lifecore Biomedical, Inc. \De\'s Current Deferred Revenue amounted to $9.0 million in Q4 2024, which was up 473.26% from $9.3 million recorded in Q3 2024.
  • Lifecore Biomedical, Inc. \De\'s 5-year Current Deferred Revenue high stood at $10.6 million for Q2 2024, and its period low was $287000.0 during Q2 2021.
  • For the 5-year period, Lifecore Biomedical, Inc. \De\'s Current Deferred Revenue averaged around $3.6 million, with its median value being $1.1 million (2021).
  • Its Current Deferred Revenue has fluctuated over the past 5 years, first tumbled by 5194.4% in 2020, then surged by 114533.0% in 2023.
  • Over the past 5 years, Lifecore Biomedical, Inc. \De\'s Current Deferred Revenue (Quarter) stood at $297000.0 in 2020, then soared by 225.59% to $967000.0 in 2021, then dropped by 24.41% to $731000.0 in 2022, then surged by 1076.47% to $8.6 million in 2023, then grew by 4.73% to $9.0 million in 2024.
  • Its last three reported values are $9.0 million in Q4 2024, $9.3 million for Q3 2024, and $10.6 million during Q2 2024.